Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab PK/PD and Tolerability in Healthy Subjects
NCT02576951Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Primary completion
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of galcanezumab in migraine and Cluster Headache (CH), sponsored by Eli Lilly and Company. Started Oct 2015; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraineCluster Headache (CH)
Beyond the preview
Go deeper on NCT02576951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576951.